Covid Drugs
Covid Drugs News
Health
WHO approves two new treatments for COVID-19: All you need to know about Baricitinib and Sotrovimab
The news comes as Omicron cases is adding pressure on the already-stressed health infrastructure around the world
COVID-19 treatment: Centre plans to create live dashboard to monitor availability of key drugs
The move is driven by the learnings from the second wave when COVID-19 critical medicines were hoarded and blackmarketed causing shortages in the market
Health
Optimus Pharma to launch anti-COVID pill Molnupiravir next week; all you need to know
Molnupiravir, developed by US-based biotechnology company Ridgeback Biotherapeutics in collaboration with US pharma giant Merck, was approved for emergency use in India on Tuesday
COVID-19 crisis in India: Rampant black-marketing during second wave, 70% people paid extra for ambulances, 36% for oxygen
Local Circles in a survey finds 50% of those who were overcharged for the ambulance were forced to pay 500% or more than the regular price. Ten percent were charged '100-500% more than regular price' for the ambulance
GST Council meeting on Friday; tax concession to 11 COVID drugs, bringing petrol and diesel under GST on cards
Tax rate on Amphotericin B, Tocilizumab was cut to 'Nil', while Remdesivir and Heparin was reduced to five percent in June 2021.
Health
A blood test can tell which COVID-19 patient should get steroid treatment and who would react adversely to it
The study suggested steroid therapy may benefit patients with severe inflammation, but may negatively impact those with less severe inflammation
Health
COVID-19 Immunity: Lancet study suggests herd immunity may not be possible, antibodies found only in 5% of test population in Spain
Herd immunity of importance as for the pandemic to be over, enough people in a community have to develop immunity against the coronavirus either after getting the disease or through vaccination
Health
Mylan's remdesivir to cost Rs 4,800 per 100 mg vial in India, 80% cheaper than price tag in wealthy nations
Gilead priced remdesivir at $2,340 per patient for rich nations and agreed to send nearly all of its supply of the drug to the United States over the next three months